We are pleased to sponsor the Swiss NASH Foundation launched in 2019 by Pr Jean-François Dufour. Its mission is to raise awareness and increase the knowledge about NASH and fatty liver in general. Through funding innovative research projects on NASH diagnostics, treatment and patient management, the foundation is joining the fight against this epidemic disease.
ENYO Pharma is in the Top 50 of the EIC ScalingUp List, in the Health Track. We were selected out of a universe of 3,000+ deeptech startups, as funded so far by the European Innovation Council (EIC) or SME Instrument. This is a fantastic business support for the growth of the company during this pivotal year.
ENYO Pharma has been highlighted in the “Best of The Liver Meeting 2021” for the oral presentation describing Vonafexor’s key effects after 12 weeks of treatment on liver and kidney functions in NASH patients, given by the LIVIFY Principal Investigator Pr Stephen Harrison during the Late Breaking Session 1 Sunday, November the 14th.
Following the positive proof-of-concept data from 203 study of Vonafexor in combination with pegylated-Interferon (peg-IFN) in viremic patients with chronic hepatitis B (CHB), a new collaboration was initiated with the team of David Durantel at the International Center for Research in Infectiology (CIRI – INSERM U1111, https://ciri.ens-lyon.fr/teams/HepVir).
ENYO Pharma is featured in the 2021 edition of Biomim’BOOK, the first book dedicated to actors and stakeholders in Biomimetism and Bio-inspiration.
To see the full book: https://www.flickr.com/photos/biomimexpo/sets/72157718879047022/
To see ENYO Pharma double page: BIOMIM_BOOK 2021_ENYO PHARMA